Evidence map›Paper›PMID 41591841›Full record

ArticleNucleic acids research2026

Critical structural perturbations of ribozyme active sites induced by 2'-O-methylation commonly used in structural studies.

Sélène Forget, Guillaume Stirnemann

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sélène ForgetCPCV Lab, Department of Chemistry, École Normale Supérieure - PSL University, Sorbonne University, CNRS, 24 rue Lhomond, 75005 Paris, France.
Guillaume StirnemannCPCV Lab, Department of Chemistry, École Normale Supérieure - PSL University, Sorbonne University, CNRS, 24 rue Lhomond, 75005 Paris, France.ORCID 0000-0002-5631-5699

Funding

European Research Council 757111European Research Council H2020/2014-2020
6 · The paper itself

Abstract

Some naturally occurring ribozymes can catalyze self-cleavage reactions through a 2'-OH group. Consequently, experimental structures of pre-catalytic states often require chemical modifications of the 2'-OH, such as its removal or methylation. However, the impact of these chemical modifications on the active site structure remains largely unexplored, which raises important questions since methylated structures are often taken as being representative of pre-catalytic states. Here, we employ extensive atomistic simulations critically compared with and fine-tuned on experimental data, and we revisit experimental results to show that 2'-O-methylation critically affects reactant geometries and, therefore, the possible reaction mechanisms inferred from the structures. Our results also challenge the common assumption that 2'-O-methylation stabilizes the C3'-endo puckering conformation. Our findings, consistent with recent experimental data on ribosome structure, reveal that this effect is highly sensitive to the local secondary structure and is often overstated. For three investigated small-cleaving ribozymes, the C2'-endo conformation observed for chemically modified active site residues through 2'-O-methylation is not stable upon methyl group removal to obtain the catalytically relevant hydroxylated state. This suggests that these geometries arise primarily from a combination of steric hindrances and electrostatic interactions with the surrounding environment rather than intrinsic conformational preferences of the ribose upon methylation.

Indexed as

RNA, CatalyticCatalytic DomainMethylationModels, MolecularMolecular Dynamics SimulationNucleic Acid ConformationRNA MethylationRNA, Catalytic

Identifiers

PMID41591841
PMCPMC12839545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.